Neurofibromatosis 2 (NF2) is an autosomal dominant disorder characterized by the occurrence of bilateral acoustic neuromas, as well as meningiomas and schwannomas. The gene locus for NF2 resides on chromosome 22q12 and has been cloned recently. Neurilemmomatosis is characterized by multiple cutaneous and spinal neurilemmomas without other signs of NFl or NF2. Many cases with this disorder include the diagnosis of neurofibromatosis or other rare diseases unexplained by current nosology. In this study, we analyzed the peripheral leukocytes and tissue from cutaneous neurilemmomas of seven pa-T he term ne urofibromatosis (NF) has been used to describe two clini cally and gene ti cally distinct herita ble di sorde rs. NFl , whose gene was cloned in 1990 [1 -3] , is charac teri zed by tumors of the periph.eral nervo us sys tem, cafe au lait spo ts , and Lisch nodules. T he gene locus fo r NFl resides o n chromosome 17 q 11. 2 [4] . The N Fl gene produ ct (neurofibromin) to a large degree share s a common sequence homology w ith the yeast IRA! and IRA2 proteins and with the m ammal ian ras guanosine triphosphatase activator protein, p1 20 GAP [5] [6] [7] . T he second type ofneurofibromatosis, NF2, is chara cteri zed by the occurrence of bilate ral aco usti c neuromas as w e IJ as m eningiomas, ependymomas, and sc hwalU1 om as. In contrast to NFl, cafe au lait spots and neurofibro mas are rare, and Lisch nodules are absent; however, posterior subcapsul ar cataracts occur in half of patients with NF2 . The gene respo nsibl e fo r NF2 ha s been mapped to chromosome 22q12 [8] and clo ned recentl y [9 ,10]. N e uriJ emmomatosis, first reported by Niimura in 1973 [11] , is characteri zed by multiple p e riph e ral (cutaneollS neurilemmomas) and spin al schwannomas, without acoustic tumors or the other sign s of N Fl o r N F2. In neuril emmomas, the tumor consists ofSchwann cells.
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Abbre viatio ns: NF, Il c uro fibrom ,n os is; SSC P, singl c-strand confo rmation po lymorphism . tients with neurilemmomatosis using DNA markers for different regions of chromosome 22. We detected allelic losses in three of seven tumors from seven patients with a probe for the NF2 region of the long arm of chromosome 22 and the germ-line mutations in two of three tumors from the same three patients. Mutations in the NF2 gene were a deletion from at least codon 334 to 579 and G insertion at codon 42 . We conclude that the neurilemmomatosis locus lies within the NF2 region and that these diseases might be identical. Key IVord: gene loclls. ] It west Dertllatol 104: [74] [75] [76] [77] 1995 product to single-strand conformation polymorphism '(SSCP) analysis .
MATERIALS AND METHODS
Patients and Samplcs Seven cutaneous tumor samples from seven patients were studied . Thc clinica l information regarding these patients is given in Table I . Six of the patients were male and one was female . None of the patients had a rnmiJy history. ne urologic disorders, or posterior subcapsular cataracts. The tissue samples were obtained at surge ry. Histologic diagnoses were made on hcmatoxyl in/ eosin-stained, formalin-fixed, paraffin-embedded sections of each tumor. The remaining portion of the tumor was frozen immediately in liquid nitrogen and stored at -BO°C until isolation of the DNA. Thc tumor contained greater than 70% tumor cells. Norma l DNA wa s obtained from leukocytes isolated with 5"!', dextran.
DNA Extraction Frozen tissue samplcs were ground to a very fine powder in liquid nitrogcn. The powder and leukocytes were digested in 50 mM Tris HCI (PH 7.5) , 150 mM NaCI , 50 mM ethylenediamine tetraa cctic acid (EDTA), 1% sodium dodecylsulf.1te , and 1 mg/ml proteinase K at 37°C overnight. The Iysates were extracted with phenol:chloroform: isoamyl alcohol (25:24:1) and precipitated with ethanol. The DNA pellet was dried and wa s resuspendcd in 10 mM Tris HCI (PH 7.5) and 1 mM EDTA (pH 8.0).
Probes The fo ll owing DNA markers on chromosome 22 w ere used: D22S9 , D22S1, cEW (Ewing Sarcoma breakpoint) . L1F (Icukemia inhibitory fa ctor), D22S15 , D22S32, and MJ3 (myoglobin locus). The probes for D22S1 and D22S32 were supplied by the Japanese Cancer Research R csources Bank. The probe fo r D22S15 was kindly provided by Dr. Kurnit, and the others were supplied by Dr. Nakamura (Cancer Institute, Tokyo, Japan).
Southern Hybridization Five micrograms. of DNA from blood and tumor pairs was digested with the appropriate restriction enzyme, electrophorescd on 1.0% agarose gels, and tran sferred to nylon membranes (Pall Biodyne transfer m e mbrane) , whi ch w e re hybridized with plasmid DNA probes labeled with [a -32 P]dCTP by random primer extension [12] . To eliminate the background of repetitive sequences, we add ed 125 f. glycol 8000, 10% sodium dodecylsul f.1te).
[n addition, before adding membrancs, wc preincubatcd [J2 P]_labcled probc DNA (2 X 10" cpm/ ml) in hybridi zatio n so lu tion at 65°C for 1 h. T he membran e was hybridi zed for approximately 12 h at 65°C, washed once in 2 X sodium citratc/sodium chloride buffcr fo r 15 min at room temperature and twice for 15 min at 65°C in 0.1 X sodium citrate/sod ium chI oride buffcr and 0.1 % sodium dodecylsul fate, and thcn cxposed to x-ray film for 12-48 h at -70°C. The membranes were stripp ed in 004 N NaOH and hybridized repeatcdly.
Allele Loss Allclic loss was in fe rred w hen the intcnsity of onc aUel e in the tumor tissuc was less than 50% of the othcr allele co mpared to the intensity of the two alleles in the corresponding normal sample , as measured by densitometry. Loss of heterozygosity was distinguish ed from chromosome duplication by no rmalizing the signal for the chromosome-22 probc to those obtained when the sa me bl ots werc rehybridized with probes fo r loci on oth e r ChrOITI OSO ln es, as a co n tro l of c hrOlll0S0nuli con tent.
PCR Amplification Oligonucleotide primer pairs of the NFl gene and thc NF2 gene used for the PC R -SSC P analysis havc been dcscribed by Cawthon ci nl [2] and Roulea u cl nl [10] (Table IT) . DNA sa mpl es wcre amplified using PCR (l min at 94°C. 2 min at 55°C, alld 3 mill at 72°C, 30 times). Twcnty-microliter PC R rcactions (100 ng of DNA , 1.25 mM of each dNTP, 50 mM KCI, 1. 25 mM MgCI 2 . 10 mM T ris pH 804, 0.5 U Taq polymerase, 004 p.l of3000 C i [a-J2 Pjd CTP/ mm ol) with mineral oil were run OJ] a PCR 9600 machinc (Perkin Elmer Cetus).
SSCP Analysis PC R products were diluted 10-fo ld using a buffc r consisting of 20 mM EDTA, 0.05% bromophcnol blu e, and 0.05%, ",ylenc cyanol, and the n heated at 95°C for 5 min to dcnaturc the DNA. Samples werc appli ed to ;1 j 0% ncutral polyacrylamide gel (4 9:1 ratio of acrylamidc to methyl ene-bis-acrylamide) containing 0.1 M Tris-borate, 2 mM EDTA. by the additio n of 5'X. glycerol to the ge l so luti on. Elcctroph oresis was
DNA Scqucncing Normal D NA from a paticnt who showed allelic loss in the tumor was amplifi ed by PCR using the same primers. The PCR products were purificd by a Ccntri con 30 column (Amicon) and amplified using 3.2 pm ol of upstrea m or dow nstream primcr. T hc product was sequenced dircctly using the dideoxy chain termin ation method witl, Taq polymerase on thc Applied Biosystems DNA sequenccr (Applied BioSystems).
R ESULTS
W e d etected a loss of h eterozygosity for th e DNA m arker (D22S15) in o n e of seven tumor sampl es (Fig lA) . The larger all elic restriction fragments (3.1 kbp) seen in the BanII di gest were lost in a tumor from case 2.
In an additional tumor, an intens ity comp arison of the bands using a d ensitometer indicated a h e mi zygou s d eletion of t he sequ e n ces a t D22S15 (Fig lB) . T h e h y bridi zation signals corresponding to the del e ted all ele were estimated to b e diminished by 50'Yo . T h ereforc, a Ue lic losses were shown o n th e long arm s of c hromo som e 22 at D22S15 in two of seven t um o rs.
Ara i cf al [13] reported one NF2 patient who was discovered to h ave chromosome translo cations t(4;·22)(q 12;q12.2). T h ey th o u g ht that this tra n slo cation was disruptin g th e NF2 gen e and thus ca u sing th e disease. Fluorescent ill silll h ybridizatio n and pulsed-field gel anal yses reveale d that th e brea kpoint la y b etween the LIF loc us and the DNA marker D22S1. T h e ph ys ical distance from the LIF locus to D22S1 is 2 cM . They obtained ap proximately 1 m egabase of yeast a rtifi cial c hro moso m e clones aro und the LIF locu s involvin g the NF2 t(4;22) tra n slocation brea kpo int region.
T h e LIF pro b e detected all eli c losses in two of seven tumors, from cases 2 and 7. Using an e5 probe, o n the e ndpoint of a yeast artifi cial c hro mosom e clone, the signal from t h e t um ors was redu ced dra maticall y in cases 1, 2, and 7 (Fig lC) . However, a proximal cosmid clone (E wing SaTcoma breakpoints, cEW) to e5 reveale d no sig nifi ca nt d e letions of DNA in t h e tumors. Data are summ arized in Fig 2 . SSCP a nal ysis of the NFl gen e of seven patients sh owed a normal patte rn of SSCP bands. No gross alte rations wcre seen in th e PCR product ofNF2 gen e amp li fied fro m gen o mi c DNA; h owever , o n e tumor sa mpl e (case 2) did n ot amplifY u sin g set-4 . set-5, and set-6 Table II primers. Complete deletion from at least codon 334 to 579 was detected in the tumor of case 2 (case 3 in Fig 3) . Figure 4 shows the results from direc t sequencing of PCR product amplifi ed from the set 1 ofNF2 gen e in normal DNA from case i. Direct seq u encing revealed a G insertion at codon 42, which caused a frame shift.
DISCUSSION
Bilateral aco u stic n euromas· (central n e urofibromatosis), described in 1822 by Wishart [14] , were classified as neurofibromatosis 2 (NF2) in 1988 by the N ation al Institutes of Hea lth Consensus D e velopment Conference [15] . NF2 is an autosoma l dominant disorder with an in c idence of about one in 50,000 . The number of patie nts with NF2 is es timate d to b e about 7000, and every year 150 n e w patients are born in Japan . During the last 25 years, 1242 patients with NFl and 48 patients with NF2 were examlll e d and treated h e re atJikei University and Tokyo Unive rsity. The patie nts with NF2 d eveloped mu ltiple tumors of the n ervo u s system, including nerilemmomas and m eni ngiomas. The studies for loss of h e te rozygosity in both tumors ha ve suggested that the loci of these genes are located on the long arm of c hromosom e 22. In acoustic n e uroma s, seven of21 tumors (33%) showe d loss of h e terozygo sity ofloci o n hum an chromosome 22 [16] . These n e urile mmomas and diagnosis is usually made by a denl1atologist when cutaneous neurilemmomas develop. In this study, using probes that span the NF2 gene, we fowld partial monosomy of chromosome 22 in three of seven cutaneous neurilemmomas (Fig 2) . SSCP analysis of the NFl gene of neurilemmomatosis patients showed a nonnal pattenl of SSCP bands. We detected the germ-line mutations in two of three tumors from the same three patients. Mutations in the NF2 gene were deletion from codon 334 to 579 at least, and G insertion at codon 42. This finding suggests that the neurilemmomatosis locus lies within the NF2 region and that these diseases might be identical. Patients with neurilemmomatosis eventually may develop acoustic neuromas, and tills neurilemmomatosis may be NF2 without acoustic neuromas. The patients with NF2 are prone to multiple neurilemmomas, including cutaneous and extracutaneous tunlors, whereas the patients with NFl may have multiple neurofibromas. Therefore, we would rather use the name neurilemmomatosis instead of NF2.
